NDC 17856-3030-2 - Rugby Nicotine Polacrilex Gum, Original Flavor
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 17856-3030
- Requested NDC
- 17856-3030-2
- Package NDCs from labels
- 17856-3030-2, 17856-3030-1
- Manufacturer
- ATLANTIC BIOLOGICALS CORP.
- Effective date
- 2025-06-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Nicotine Polacrilex Gum 2 mg Original Flavor - Rugby | ATLANTIC BIOLOGICALS CORP. | 2025-06-27 | HUMAN OTC DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| Effective | Related label |
|---|---|
| 2024-04-15 | Nicotine Polacrilex Gum 2 mg Original Flavor - Rugby |
| 2024-01-30 | Nicotine Polacrilex Gum 2 mg Original Flavor - Rugby |
| 2021-07-06 | Nicotine Polacrilex Gum 2 mg Original Flavor - Rugby |
| 2020-01-31 | Nicotine Polacrilex Gum 2 mg Original Flavor - Rugby |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-3030-1 | Rugby Nicotine Polacrilex Gum, Original Flavor | 50 in 1 CASE | GUM, CHEWING | 50 | 5 | |
| 17856-3030-2 | Rugby Nicotine Polacrilex Gum, Original Flavor | 1 in 1 POUCH | GUM, CHEWING | 1 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-3030 | RUGBY NICOTINE POLACRILEX GUM, ORIGINAL FLAVOR (NICOTINE POLACRILEX) GUM, CHEWING [ATLANTIC BIOLOGICALS CORP.] | 4 | Current NDC, Legacy NDC, 2 package rows | 20240417_57e08517-4c8a-487a-bfbe-2a43f105f4b9.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| signature care nicotine | NICOTINE POLACRILEX | Safeway | 22010ed8-7fa6-402a-a314-523538183a55 | 2018-11-01 | Warnings | 6M3C89ZY6R |
| signature care nicotine | NICOTINE POLACRILEX | Safeway | 664c3faf-7cab-4bda-8987-07acb8e1142b | 2018-10-31 | Warnings | 6M3C89ZY6R |
| exchange select nicotine | NICOTINE POLACRILEX | Army & Air Force Exchange Service | e926cf6f-305a-4912-be07-a45bb7905822 | 2018-09-21 | Warnings | 6M3C89ZY6R |
| SODIUM BICARBONATE | SODIUM BICARBONATE | Aphena Pharma Solutions - Tennessee, LLC | 15605a6d-6c90-47d5-9d1f-f66a3f27d5fc | 2017-12-13 | Warnings | 8MDF5V39QO |
| berkley and jensen nicotine | NICOTINE POLACRILEX | BJWC | 357123fc-0972-4683-ab52-f95d46c1b6c9 | 2017-11-09 | Warnings | 6M3C89ZY6R |
| Sodium Bicarbonate Antacid | SODIUM BICARBONATE | Richmond Pharmaceuticals, Inc. | e0b2f0d3-3849-4bdf-b3d4-e14e520e36ce | 2017-11-01 | Warnings | 8MDF5V39QO |
| Homeoplex D | GLYCERINUM, PHYTOLACCA DECANDRA, TARAXACUM OFFICINALE, ARSENICUM ALBUM, NITRICUM ACIDUM, NUX VOMICA, PETROLEUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, ACETYLSALICYLICUM ACIDUM, GLONOINUM, INSULINUM (SUIS), LITHIUM CARBONICUM, THYROIDINUM (SUIS), SALICYLICUM ACIDUM, ADRENOCORTICOTROPHIN, CORTISONE ACETICUM, EUGENOL, STEARYL ALCOHOL, XYLITOL, FOLLICULINUM, BENZOICUM ACIDUM, CHLORINUM, POTASSIUM SORBATE, SORBITOL, RESORCINUM, BENZYL ALCOHOL, LACTICUM ACIDUM, ISOPROPYL PALMITATE, BORICUM ACIDUM, ACETICUM ACIDUM, | Supplement Clinic, LLC. | cd6b48ab-3566-484d-8deb-15ef6f8e7e8f | 2017-11-01 | Warnings | 506T60A25R |
| SODIUM BICARBONATE | SODIUM BICARBONATE | Richmond Pharmaceuticals, Inc. | fa10d93d-b3ed-4675-a117-f573d9e72bca | 2017-10-30 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Exela Pharma Sciences, LLC | e9698a4f-1a95-4f28-a945-e8009d1d6dd4 | 2017-09-27 | Warnings, Adverse reactions | 8MDF5V39QO |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.